EANS-Adhoc: Epigenomics AG
Ad hoc (§15 WpHG): Epigenomics AG: Notice of Loss
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
Company Information
25.03.2009
Berlin, Germany, - The Executive Board of Epigenomics AG notifies that using its due diligence it has to be assumed that using German GAAP HGB) accounting losses of more than half of the ordinary share capital have been incurred. In addition to the anticipated operating losses in the first three months of the financial year, a one-time effect not affecting liquidity has caused reaching this threshold. This one-time effect does not have any implications on Epigenomics' consolidated group financials under IFRS.
In agreement with § 92 para. 1 AktG (German Stock Companies Act) the Executive Board will summon without undue delay a general shareholder meeting to notify all shareholders of the losses. The general meeting to be called will according to current planning be combined with the Company's Annual General Shareholders Meeting 2009. The Annual General Shareholders Meeting 2009 will be held on May 11, 2009, 11:00 am CET at the premises of Deutsche Bank AG, Unter den Linden 13- 15 (Entrance Charlottenstraße), 10117 Berlin.
End of Notification
Further Information
The Executive Board will be available for questions and further clarifying statements during the regular annual press conference and analyst meeting 2009 that will be held on Tuesday, March 31, 2009 at 10 am to 12 noon CET at the premises of the Villa Bonn - Frankfurter Gesellschaft für Handel Industrie und Wirtschaft in Frankfurt am Main as well as during the regular earnings call at 3 pm on the same day (Dial-in number within Germany: +49 868 71 790; dial-in number from outside Germany: +1 212 444 0297)
Legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
end of announcement euro adhoc
Further inquiry note:
Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com
Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade